CN100378107C - 唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途 - Google Patents

唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途 Download PDF

Info

Publication number
CN100378107C
CN100378107C CNB028100026A CN02810002A CN100378107C CN 100378107 C CN100378107 C CN 100378107C CN B028100026 A CNB028100026 A CN B028100026A CN 02810002 A CN02810002 A CN 02810002A CN 100378107 C CN100378107 C CN 100378107C
Authority
CN
China
Prior art keywords
formula
group
compound
pyrimidine
nitrophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028100026A
Other languages
English (en)
Chinese (zh)
Other versions
CN1509291A (zh
Inventor
G·博尔德
P·W·曼利
A·马丁-科勒
U·塞坎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1509291A publication Critical patent/CN1509291A/zh
Application granted granted Critical
Publication of CN100378107C publication Critical patent/CN100378107C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB028100026A 2001-05-14 2002-05-13 唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途 Expired - Fee Related CN100378107C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH0873/2001 2001-05-14
CH8732001 2001-05-14
CH0873/01 2001-05-14

Publications (2)

Publication Number Publication Date
CN1509291A CN1509291A (zh) 2004-06-30
CN100378107C true CN100378107C (zh) 2008-04-02

Family

ID=4544205

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028100026A Expired - Fee Related CN100378107C (zh) 2001-05-14 2002-05-13 唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途

Country Status (12)

Country Link
US (1) US7294633B2 (cg-RX-API-DMAC10.html)
EP (1) EP1390371B1 (cg-RX-API-DMAC10.html)
JP (1) JP4155827B2 (cg-RX-API-DMAC10.html)
CN (1) CN100378107C (cg-RX-API-DMAC10.html)
AT (1) ATE319718T1 (cg-RX-API-DMAC10.html)
BR (1) BR0209645A (cg-RX-API-DMAC10.html)
CA (1) CA2449188A1 (cg-RX-API-DMAC10.html)
DE (1) DE60209721T2 (cg-RX-API-DMAC10.html)
DK (1) DK1390371T3 (cg-RX-API-DMAC10.html)
ES (1) ES2259707T3 (cg-RX-API-DMAC10.html)
PT (1) PT1390371E (cg-RX-API-DMAC10.html)
WO (1) WO2002092603A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781790A (zh) * 2011-07-07 2014-05-07 赛诺菲 具有噁唑并[5,4-b]吡啶环的羧酸衍生物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689753A4 (en) * 2003-12-04 2010-07-07 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
KR20050091462A (ko) * 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
JPWO2005095419A1 (ja) * 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
EP1874769B1 (de) 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
DE102005061170A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
DE102005061171A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
EP3219319A1 (en) * 2006-06-22 2017-09-20 Nippon Chemiphar Co., Ltd. Agent for overcoming resistance to anti-cancer agent
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
EP2318415B1 (en) * 2008-07-15 2013-02-20 Sanofi Oxazolopyrimidines as edg-1 receptor agonists
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
CN101899057A (zh) * 2010-07-21 2010-12-01 中国药科大学 嘧啶并噁唑衍生物的一种制备方法及其在医学上的用途
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103087077B (zh) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103360407B (zh) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN104650111A (zh) * 2015-01-14 2015-05-27 中国药科大学 芳基脲及芳基酰胺取代的噁唑并嘧啶类化合物及其制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096749A (en) * 1994-05-03 2000-08-01 Novartis Corporation Pyrrolopyrimidine derivatives having pharmacological activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137879A (en) 1990-03-30 1992-08-11 Dowelanco Furopyrimidin-4-imine derivatives
US5227387A (en) * 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
JPH1184248A (ja) * 1997-09-12 1999-03-26 Nikon Corp 反射屈折縮小光学系
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096749A (en) * 1994-05-03 2000-08-01 Novartis Corporation Pyrrolopyrimidine derivatives having pharmacological activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781790A (zh) * 2011-07-07 2014-05-07 赛诺菲 具有噁唑并[5,4-b]吡啶环的羧酸衍生物

Also Published As

Publication number Publication date
US20040152892A1 (en) 2004-08-05
CN1509291A (zh) 2004-06-30
ES2259707T3 (es) 2006-10-16
DK1390371T3 (da) 2006-06-19
WO2002092603A1 (en) 2002-11-21
JP4155827B2 (ja) 2008-09-24
BR0209645A (pt) 2004-07-06
EP1390371B1 (en) 2006-03-08
PT1390371E (pt) 2006-07-31
DE60209721D1 (de) 2006-05-04
JP2005508855A (ja) 2005-04-07
CA2449188A1 (en) 2002-11-21
US7294633B2 (en) 2007-11-13
ATE319718T1 (de) 2006-03-15
EP1390371A1 (en) 2004-02-25
DE60209721T2 (de) 2006-09-07

Similar Documents

Publication Publication Date Title
AU747920B2 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists
CN116406271B (zh) 双环类化合物
US7294633B2 (en) Oxazolo-and furopyrimidines and their use in medicaments against tumors
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
Wang et al. Synthesis and anticancer activity evaluation of a series of [1, 2, 4] triazolo [1, 5-a] pyridinylpyridines in vitro and in vivo
CN104203242B (zh) 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
JP2016138103A (ja) Ｎａｍｐｔの阻害のための新規な化合物及び組成物
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
JP2005538992A (ja) キナーゼ阻害剤
TW200304818A (en) Kinase inhibitors
MX2013000617A (es) Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
JPWO2005095419A1 (ja) チアゾロピリミジン誘導体
KR101274986B1 (ko) 이미다조피리딘 유도체, 이를 포함하는 ＰＩ3Ｋ 및/또는 ｍＴＯＲ 저해제용 약학 조성물 및 ＰＩ3Ｋ 및/또는 ｍＴＯＲ과 연관된 질환 치료용 약학 조성물
CN104507936A (zh) 吡啶基和嘧啶基亚砜和砜衍生物
EP0853616B1 (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
SK5912002A3 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
CN119013279A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
CN115768757B (zh) Cd206调节剂及其用途和制备方法
JP2021519297A (ja) Ｔｒｋキナーゼ阻害剤としての大環状化合物
JP2023538091A (ja) Ｂｔｋ阻害剤としての複素環式化合物
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
TW202515544A (zh) 作為ｃ－ｋｉｔ激酶抑制劑的醫藥化合物及組合物
CN121925419A (zh) 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
TWI820414B (zh) 喹唑啉類化合物、製備方法及其應用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080402

Termination date: 20110513